Since CXCL8 is a prominent regulator of BCSC activity, a combined treatment of CXCR2 inhibitors and current HER2-targeted therapies is predicted to be an effective regimen to decrease CSC activity and increase survival in HER2-positive patients with breast cancer (90). Here, CXCR2 is linked to breast cancer.